3530 JOHN HOPKINS COURT, SAN DIEGO, CA
Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries
ImmunityBio Enters Convertible Note Amendment for $505 Million
Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
Saudi FDA Grants Accelerated Approval to ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
FY 2024
Q3
Q2
Q1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Definitive Information Statement
Preliminary Information Statement
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload